Skip to main content
OpenTrials
Completed

NCT Number: NCT05500534

TELAXMAN - Laser Lithotripsy With Automatic Real-time Stone Recognition

Urolithiasis is an extremely common disease affecting about 12% of the world population with increasing tendency. Urinary stones are sediments that form in the kidney from crystals, such as calcium oxalate.

Currently, urological endoscopy with laser lithotripsy represents the leading and most frequently used method for the treatment of urinary stones of different localization, size and composition.

Surgical urology, including interventional stone treatment, is highly influenced by technology. With regard to fragmentation properties and effectiveness for all stone types Holmium:yttrium-aluminium-garnet (Ho:YAG) laser lithotripsy has become the standard technology to disintegrate urinary calculi.

In addition, other kinds of lasers are emerging, such as the thulium fiber laser (TFL); a new solid-state, diode-pumped laser that may provide urologists with increased options for stone treatment.

While urolithiasis treatment in general and laser lithotripsy in specific rarely goes along with major complications, recent studies have shown that there are possible indirect risks to the treatment with lasers, such as thermal damages to the urinary tract even at low-power settings if inadequate irrigation is applied. Sufficient irrigation is mandatory to perform safe Ho:YAG laser lithotripsy.

The RevoLix HTL+ automatic real-time stone detection module was developed to overcome these limitations and improve the safety of the patient with regard to potential thermal damages.

The objective of this clinical investigation is to assess the feasibility of stone recognition and disintegration with the RevoLix HTL+ in clinical conditions and to identify hypotheses to be used in future clinical investigations.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Lithotripsy, Laser

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Universitätsklinikum Freiburg

Freiburg im Breisgau, 79106, Germany

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject scheduled for laser lithotripsy
  • Subject aged 18 or older
  • Subject able to give consent
  • Informed consent documented by signature

Exclusion criteria

  • Subject pregnant or nursing
  • Subject requiring emergency lithotripsy
  • Contraindication for the surgical procedure:
  • Positive urine culture,
  • Unfit for general anesthesia,
  • Therapeutic anticoagulation, or systemic infection

Treatment and study plan

Laser lithotripsy with stone recognition

Device

Application of Revolix HTL+ which features automatic real-time stone recognition

Laser lithortripsy

Other

Standard laser lithotripsy

Primary outcomes

  1. Visual assessment of stone-free status;

    Time frame: During the procedure of laser lithotripsy, which should last for a maximum of 5 hours

    Before retracting the ureteroscope, the surgeon will visualize the postoperative ureter along its entire length and record the stone-free status in the CRF, using the following scale:

    0 - No residue

    • - Residual fragments ≤4mm
    • - Residual fragments >4mm Stone-free status is the state-of-the-art methodology for the description of the lithotripsy procedure, which is performed routinely at the investigation site. It does not require any additional invasive testing or procedures and it is performed intra-operatively.

  2. Visual assessment of stone, tissue and endoscope recognition accuracy during laser lithotripsy

    Time frame: During the procedure of laser lithotripsy, which should last for a maximum of 5 hours

    During the procedure, the surgeon will record every incidence of misrecognition by the RevoLix HTL+. Misrecognition is defined as inadequate laser pulse release on healthy tissue or endoscope.

  3. Safety of device - assessment of device deficiencies

    Time frame: During laser lithotripsy (duration of max 5 hours)

    Safety of the device shall be evaluated by systematically reporting DDs and by monitoring the frequency and incidence of these events

  4. Safety of device - assessment of adverse events during the intervention

    Time frame: During laser lithotripsy (duration of max 5 hours)

    Safety of the device shall be evaluated by systematically reporting AEs and SAEs and by monitoring the frequency and incidence of these events

  5. Safety of device - assessment of adverse events during the follow up time

    Time frame: During the follow up time (up to 3 months)

    Safety of the device shall be evaluated by systematically reporting AEs and SAEs and by monitoring the frequency and incidence of these events

  6. New risk identification during the intervention

    Time frame: Within 12 hours after the intervention

    The practitioner will be asked to identify any new risks arising during laser lithotripsy using the investigational device

  7. New risk identification during the follow up time

    Time frame: During the follow up time (up to 3 months)

    The practitioner will be asked to identify any new risks related to the investigational device during the follow up time

Secondary outcomes

  1. Total laser emitted energy (J)

    Time frame: Immediately (up to 1 hour) after the end of the intervention

    Total laser emitted energy is recorded by the laser system during each procedure. This data will be extracted after each procedure for the investigational arm and at the end of the investigation for the matching control arm.

  2. Procedure duration (min)

    Time frame: Immediately (up to 1 hour) after the end of the intervention

    Procedure duration will be recorded in the CRF as the time from endoscope insertion to retraction (Schnitt-Naht Zeit).

  3. PULS classification of potential lesions visible via endoscopy immediately after the procedure

    Time frame: During the procedure of laser lithotripsy, which should last for a maximum of 5 hours

    Before retracting the ureteroscope, the surgeon will visualize the postoperative ureter along its entire length and record PULS classification in the CRF.

    PULS is a 5 grades scale (0 - No lesion; 1 - Superficial mucosal lesion and/or significant mucosal oedema/hematoma; 2 - Submucosal lesion; 3 - Perforation with less than 50% partial transection; 4 - Perforation with more than 50% partial transection; 5 - Complete transection), in which lesions are graded independently of their location and extent. In case of multiple lesions, the most severe grading is applied.

  4. Usability and workflow assessment (surgeon's questionnaire)

    Time frame: Within 12 hours after the intervention

    Immediately after his/her first procedure with RevoLix HTL+, the surgeon will fill in a questionnaire regarding the different aspects of the laser system.

Sponsors and collaborators

Lead sponsor

LISA Laser Products GmbH

Industry

Registry information

Official study title

Exploratory Feasibility Study of a Novel Laser System for Endoscopic Disintegration of Urinary Stones With Automatic Real-time Stone Recognition

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Aug 15, 2022
Registry last updated
Aug 21, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.